Volume 19, Issue 7 p. 860-869

Pharmaceutical Care of Patients with Congestive Heart Failure: Interventions and Outcomes

Dr. Sumanthra Varma Ph.D.

Dr. Sumanthra Varma Ph.D.

Pharmacy Practice Research Group, School of Pharmacy, Belfast, Northern Ireland

Search for more papers by this author
Dr. James C. McElnay Ph.D.

Corresponding Author

Dr. James C. McElnay Ph.D.

Pharmacy Practice Research Group, School of Pharmacy, Belfast, Northern Ireland

Pharmacy Practice Research Group, School of Pharmacy, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern IrelandSearch for more papers by this author
Dr. Carmel M. Hughes Ph.D.

Dr. Carmel M. Hughes Ph.D.

Pharmacy Practice Research Group, School of Pharmacy, Belfast, Northern Ireland

Search for more papers by this author
Dr. A. Peter Passmore M.D.

Dr. A. Peter Passmore M.D.

Department of Geriatric Medicine, Queen's University of Belfast, Belfast, Northern Ireland

Search for more papers by this author
Dr. Mahandra Varma Ph.D.

Dr. Mahandra Varma Ph.D.

Erne Hospital, Enniskillen, Northern Ireland

Search for more papers by this author
First published: 17 January 2012
Citations: 122

Abstract

We evaluated a structured pharmaceutical care program for elderly patients (> 65 yrs) with congestive heart failure (CHF) based on objective measures of disease control, quality of life, and use of health care facilities in a randomized, controlled, longitudinal, prospective clinical trial. The 42 patients in group A received education from a pharmacist on the disease and its treatment, and lifestyle changes that could help control symptoms. Patients also were encouraged to monitor their symptoms and comply with prescribed drug therapy. If necessary, dosage regimens were simplified in liaison with hospital physicians. The 41 control patients (group B) received standard care. The following outcome measures were assessed in all patients at baseline (before the start of the trial) and at 3, 6, 9, and 12 months: 2-minute walk test, blood pressure, body weight, pulse, forced vital capacity, quality of life [disease-specific (Minnesota Living with Heart Failure questionnaire) and generic (SF-36)], knowledge of symptoms and drugs, compliance with therapy, and use of health care facilities (hospital admissions, visits to emergency room, emergency calls). Patients in group A showed improved compliance with drug therapy, which in turn improved their exercise capacity compared with those in group B; education on management of symptoms, lifestyle changes, and dietary recommendations were also of benefit. Group A patients significantly improved knowledge of their drug therapy over the 12-month study and had fewer hospital admissions compared with group B patients. They also had improved outcomes compared with group B, despite the small samples. An extension of this trial to other sites with pooling of results would provide additional evidence of the value of this structured program in elderly patients with CHF.